Pharmathen, established in 1969, has emerged as a leading in-house development partner in Europe. It specializes in the development, registration, manufacturing & life-cycle management of complex pharmaceutical technologies & generic formulations. With a portfolio of over 100 products, Pharmathen serves over 250 clients across 80 countries. It’s pipeline includes advanced long-acting injectables, sustained-release formulations & preservative-free ophthalmics manufactured in USFDA & EU-approved facilities. Pharmathen’s core technology platforms, including microspheres, nanosuspensions & nanogels, are used to develop long-acting therapies.